Dr Shang-Zhong (Sam) Xu is a reader in the Centre for Cardiovascular and Metabolic Research. He obtained his BM in clinical medicine from Shandong Medical University (1986), MSc in Pharmacology from Shanghai Medical University (1989, Shanghai) and MD in Cardiology (1996, Shanghai). He worked as a resident physician, specialist and then associate professor and consultant cardiologist (1989-1998). He was enthusiastic for medical research and moved to Leeds for PhD study (PhD, 2001, Leeds) and then postdoctoral research fellow (2001-2005, Leeds). Sam joined the Postgraduate Medical Institute and Hull York Medical School as a Lecturer in 2005 and became Senior Lecturer, and then Reader in Hull York Medical School. His research focused on ion channels, drug discovery and new target identification for cardiovascular diseases and diabetic complications.
TRPC6 Binds to and Activates Calpain, Independent of Its Channel Activity, and Regulates Podocyte Cytoskeleton, Cell Adhesion, and Motility
Farmer, L., Rollason, R., Whitcomb, D., Ni, L., Goodlif, A., Lay, A., …Welsh, G. (2019). TRPC6 Binds to and Activates Calpain, Independent of Its Channel Activity, and Regulates Podocyte Cytoskeleton, Cell Adhesion, and Motility. Journal of the American Society of Nephrology : JASN, 30(10), 1910-1924. https://doi.org/10.1681/ASN.2018070729
Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface
Li, P., Rubaiy, H. N., Chen, G., Hallett, T., Zaibi, N., Zeng, B., …Xu, S. (2019). Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface. British Journal of Pharmacology, 176, 3845–3856. https://doi.org/10.1111/bph.14788